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Neisseria gonorrhoeae is an exquisitely adapted, strictly human pathogen and the
causative agent of the sexually transmitted infection gonorrhea. This ancient human
disease remains a serious problem, occurring at high incidence globally and having a
major impact on reproductive and neonatal health. N. gonorrhoeae is rapidly evolving
into a superbug and no effective vaccine exists to prevent gonococcal infections.
Untreated or inadequately treated gonorrhea can lead to severe sequelae, including
pelvic inflammatory disease and infertility in women, epididymitis in men, and sight-
threatening conjunctivitis in infants born to infected mothers. Therefore, there is an
immediate need for accelerated research toward the identification of molecular targets for
development of drugs with new mechanisms of action and preventive vaccine(s). Global
proteomic approaches are ideally suited to guide these studies. Recent quantitative
proteomics (SILAC, iTRAQ, and ICAT) have illuminated the pathways utilized by N.
gonorrhoeae to adapt to different lifestyles and micro-ecological niches within the host,
while comparative 2D SDS-PAGE analysis has been used to elucidate spectinomycin
resistance mechanisms. Further, high-throughput examinations of cell envelopes and
naturally released membrane vesicles have unveiled the ubiquitous and differentially
expressed proteins between temporally and geographically diverse N. gonorrhoeae
isolates. This review will focus on these different approaches, emphasizing the role
of proteomics in the search for vaccine candidates. Although our knowledge of N.
gonorrhoeae has been expanded, still far less is known about this bacterium than the
closely related N. meningitidis, where genomics- and proteomics-driven studies have led
to the successful development of vaccines.
Keywords:Neisseria gonorrhoeae, gonorrhea, proteomics,molecular targets, vaccine, drugs, antibiotic resistance,
surveillance
INTRODUCTION
Gonorrhea is an ancient human disease, with references to its symptoms found in the Old Testament
of the Bible (Leviticus 15:1–3). For almost 700 years, it has been known as “the clap,” a likely
reference to the old Le Clapiers district of Paris where prostitutes were housed. This sexually
transmitted disease remains a global scourge today, causing an estimated 106 million new cases
worldwide each year WHO (2012). In the United States, gonorrhea is the second most common
sexually transmitted disease, with over 300,000 new cases, primarily affecting those between
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20 and 24 years of age, reported to the Centers for Disease
Control and Prevention (CDC) annually CDC (2013). The Gram-
negative diplococcusNeisseria gonorrhoeae, the gonococcus (GC),
is the sole cause of gonorrhea. In men, infections typically
present as profuse, localized inflammatory response of the urethra
(i.e., urethritis). In contrast, gonorrhea remains asymptomatic in
50–80% of infected women (Farley et al., 2003; WHO, 2011).
Untreated or inadequately treated gonococcal infections can
have severe consequences including epididymitis in men and
pelvic inflammatory disease and inflammation of the uterus,
ovaries and fallopian tubes in women, which can lead to
infertility. Neonatal health is also detrimentally affected by
GC infection, as this pathogen can cause a sight-threatening
conjunctivitis in infants born to infected mothers (Creighton,
2011). Additionally, infection with GC increases the risk of
HIV transmission (Tapsall, 2005). Further compounding the
difficulty in treating gonorrheal infections, through a number
of point mutations, as well as horizontally acquired genes, GC
has gained resistance to nearly all antibiotics currently in use
(Tapsall et al., 2010; Unemo and Shafer, 2014). The CDC now
recommends a combination of ceftriaxonewith either doxycycline
or azithromycin for empirical gonorrhea treatment (CDC, 2012b);
however, treatment failures with ceftriaxone have been verified
in Japan, Australia, Sweden, and Slovenia (reviewed in Unemo,
2015). Additionally, GC demonstrates remarkable heterogeneity
and strain-to-strain variability, which represent a significant
challenge in vaccine development (Zhu et al., 2011; Jerse et al.,
2014).
Immediate action is critically needed against gonorrhea before
it becomes completely untreatable. In response to this dire
possibility, the World Health Organization (WHO) published
the “Global Action Plan to Control the Spread and Impact of
Antimicrobial Resistance inNeisseria gonorrhoeae” (WHO, 2012),
and the CDC (CDC, 2012a), as well as the European Centre for
Disease Prevention and Control (ECDC; ECDC, 2012) proposed
region-specific response plans. Overall, these proposals stressed
the importance of implementing holistic action against gonorrhea,
which would encompass early prevention, diagnosis, contact
tracing, treatment, and surveillance of antimicrobial resistance
and treatment failures.
An ideal method of gonorrhea prevention would be the
development of a protective vaccine(s). Indeed, according to
model simulations, gonococcal prevalence could be reduced by
at least 90% after 20 years if all 13-year olds were given a
non-waning vaccine with 50% efficacy or a vaccine with 100%
efficacy that wanes after 7.5 years. Further, even with a non-
waning vaccine of 20% efficacy, as much as a 40% decrease in
prevalence could be anticipated (Craig et al., 2015). In line with
the WHO, CDC, and ECDC call for action, it is a prerequisite
that the anti-gonorrhea vaccine and new drug development be
made a priority. Different proteomic approaches are exceedingly
valuable to accompany the progress of effective new therapeutic
interventions by identifying vaccine and drug targets. Herein,
we guide through these different approaches in the treasure
hunt for countermeasures against gonorrhea, emphasizing the
role of proteomics in the search for GC vaccine candidates
(Figure 1).
HOW DOES A HEALTH-OBSESSED
RESEARCHER EVALUATE
AN ENERGY BAR?
WITH PROTEOMICS
As genomic approaches, whole-genome sequencing in particular,
have become relatively inexpensive and increasingly high-
throughput, with short turn around times and great resolution
in the past few years, they have grown increasingly useful in
basic research and in clinical diagnosis. The Broad Institute has
recently released the whole genome sequences of 14 GC clinical
isolates in collaboration with the Neisseria gonorrhoeae Group to
facilitate research into pathogenesis and genetic determinants of
disease states (Neisseria gonorrhoeae Group Sequencing Project,
Broad Institute of Harvard and MIT1). Additionally, multilocus
sequence typing (MLST), which characterizes isolates based
on internal fragments of housekeeping gene alleles, has been
used to cluster GC patient isolates based on phenotype (Ilina
et al., 2010). A database of MLST data for Neisseria species
has been established2, further facilitating MLST identification
and genotypic grouping of GC isolates. Genomic-derived
methodologies have identified GC iron-responsive genes (Ducey
et al., 2005), the anaerobic stimulon (Isabella and Clark, 2011),
as well as gene expression patterns during infection of the
lower female genital tract (McClure et al., 2015). In clinical
applications, the proliferation of genomic datasets has promoted
the development of nucleic acid amplification tests (NAATs),
which allow for rapid identification of GC in patient samples
without the need for culture (Low et al., 2014).
Ultimately, however, genomics is unable to capture the
complete biological complexity present. A combination of
different proteomic approaches can greatly complement genomic-
acquired data by examining the GC protein population in biofilms
or upon exposure to relevant host stimuli (Wu et al., 2010; Phillips
et al., 2012), proteins associated with drug resistance (Nabu
et al., 2014), proteome expression patterns during infection, post-
translational modifications, or by providing information about
proteins’ subcellular location, structures and protein–protein
interactions. The knowledge gained from proteomic studies can
be useful for identifyingGC in clinical samples (Gudlavalleti et al.,
2008; Carannante et al., 2015), evaluating antibiotic resistance,
and discovering potential vaccine and drug candidate proteins
(Zielke et al., 2014, 2015).
WHEN DO YOU NOT WANT
TO RECEIVE APPLAUSE?
WHEN YOU IDENTIFY “THE CLAP”
Rapidly identifying GC in clinical isolates is vital to initiate
treatment as quickly as possible to prevent the severe
consequences of untreated gonorrhea, as well as to limit the
spread of antimicrobial resistant strains. NAATs, developed
1http://www.broadinstitute.org/
2http://pubmlst.org/neisseria/
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FIGURE 1 | A treasure hunt map of proteomic approaches applied to better understand GC pathophysiology and discovery of vaccine and drug
targets. (A) Comparative proteome maps have been constructed between spectinomycin resistant (SpR) and spectinomycin sensitive (wild type; wt) GC isolates
using 2-D-SDS-PAGE. (B) Proteomic investigations (1D SDS-PAGE and ICAT) of manganese (Mn) regulation of virulence factors and oxidative stress. (C) Proteomic
profiling of GC transition from planktonic to biofilm growth using SILAC. (D) Comparative, high-throughput proteomic analyses of cell envelope and MV fractions
derived from GC strains FA1090, F62, MS11, and 1291.
with the use of genomic data, are more rapid and sensitive
than culture, which has resulted in an increase in the number
of infections detected (Unemo and Shafer, 2014; Wind et al.,
2015). Current commercially available gonococcal NAATs
are unable to satisfactorily measure antimicrobial resistance,
undermining the surveillance of antimicrobial resistance trends.
Because of this limitation, the ECDC has recommended that all
specimens positive for GC by NAAT are subsequently cultured
to monitor antimicrobial resistance trends (ECDC, 2012).
However, laboratory-developed NAATs have been utilized to
identify known genetic antimicrobial resistance determinants
against several classes of antibiotics as well as detecting the
crucial mutations conferring resistance to extended-spectrum
cephalosporins in superbug strains H041 and F89 (reviewed, by
Unemo, 2015).
As antibiotic resistance determinants continuously evolve,
the development of new detection tests is required (Unemo,
2015). Proteomics can provide sensitive, accurate, rapid, and
cost-effective methods of GC identification and determination of
antimicrobial resistance patterns in clinical samples. Proteomic
identification of bacteria is primarily performed with data
generated by matrix-assisted laser desorption ionization
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time-of-flight mass spectrometry (MALDI-TOF-MS). Unique
and representative biomarker ions can be established from intact
cell MALDI-TOF-MS analysis (van Baar, 2000; Amiri-Eliasi
and Fenselau, 2001; Fenselau and Demirev, 2001; Fagerquist
et al., 2010; Murray, 2010; Niyompanich et al., 2014). The most
important advantages in direct bacterial profiling by means
of MALDI-TOF-MS are: (1) the requirement for only a small
amount of biological material, (2) the possibility of examining
intact cells without preceding extraction and separation, (3) a fast
and straightforward procedure, and (4) high specificity in species
differentiation (Ilina et al., 2009).
One of the first examples of direct GC profiling with MALDI-
TOF-MS used surface enhanced MALDI-TOF-MS to analyze
over 350 GC strains and closely related species (Schmid et al.,
2005). These comparisons enabled the design of multilayer
artificial neural networks that revealed 20 ion peak descriptors
of positive, negative and secondary nature that were supreme for
GC identification (over 96% efficiency, a sensitivity of 95.7% and
a specificity of 97.1%). Another study used atmospheric pressure
MALDI-TOF to determine that a putative DNA binding protein
from N. meningitidis; its homolog in GC, DbhA; and acyl carrier
proteins in each species could be used as protein biomarkers
for identifying pathogenic Neisseria (Gudlavalleti et al., 2008).
Although this approach does not provide a method to distinguish
between N. meningitidis and N. gonorrhoeae, it can act as a
base upon which to build techniques for identifying pathogenic
Neisseria in clinical samples. The successful application of
MALDI-TOF-MS for GC identification has also been recently
demonstrated on 92 out of 93 isolates of gonococci collected from
2007 to 2012 as part of the European Gonococcal Antimicrobial
Surveillance Programme (Carannante et al., 2015).
Together, these studies highlight the potential of proteomic
approaches to rapidly and correctly identify GC in various clinical
isolates, which, if implemented on a larger scale, will promote
rapid initiation of treatment while still allowing antimicrobial
susceptibility testing to be performed.
WHAT DID THE BACTERIA CALL THEIR
GUERILLA WARFARE UNIT?
THE SPECTINOMYCIN RESISTANCE
In a survey of antimicrobial resistance in Southeast Asia, the
WHO Global Gonococcal Antimicrobial Surveillance Program
found that between 0.6 and 10.5 percent of isolates demonstrated
spectinomycin resistance (Bala et al., 2013). Spectinomycin
directly interacts with 16S rRNA and inhibits the elongation factor
G (EF-G)-catalyzed translocation of the peptidyl-tRNA from the
A site to the P site during protein synthesis (Bilgin et al., 1990;
Ramakrishnan andWhite, 1992). Not surprisingly, spectinomycin
resistance determinants traditionally involve mutations in 16S
rRNA (Maness et al., 1974; Galimand et al., 2000). However,
a deletion of amino acid 25 and a K26E amino acid alteration
(E. coli numbering) in the ribosomal protein S5 is a newly
identified mechanism associated with high-level spectinomycin
resistance in GC (Unemo et al., 2013). Overall, however, the in
vitro susceptibility to this aminocyclitol compound is remarkably
high worldwide and this antibiotic is an effective alternative for
treatment of anogenital gonorrhea, in particular for multidrug
resistant cases (Unemo, 2015).
The proteomic signatures of GC spectinomycin resistance
as well as cellular responses to spectinomycin treatment
were assessed through qualitative and relative quantitative
proteomics using densitometry analysis of proteins separated
by two-dimensional sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (2D SDS-PAGE) and protein identification
with MALDI-TOF-MS (Otto et al., 2012; Nabu et al., 2014).
Comparative proteome maps have been constructed between
a spectinomycin resistant (SpecR) clinical isolate and a
spectinomycin sensitive (SpecS) reference strain (ATCC
49226; Figure 1A). When the two strains were not exposed
to spectinomycin, their protein profiles were largely the same,
with EF-Tu and EF-Ts, cysteine synthase, and the septum site-
determining protein MinD upregulated in the SpecR isolate.
Additionally, MinD, oxidoreductase, and hypothetical protein
NGO1873 were shifted to a more acidic isoelectric point, and
the ribosomal protein S6 was shifted to a more basic pI in the
resistant isolate. Finally, ABC transporter substrate-binding
protein showed decreased expression and alcohol dehydrogenase
was not detected in the SpecR strain. Interestingly, in the presence
of spectinomycin, although dihydrolipoamide dehydrogenase,
peroxiredoxin, an outer membrane protein Rmp, and the 50S
ribosomal protein L7/L12 were upregulated in both strains, none
of the proteins were expressed as highly in the resistant strain as in
the wild type. Overall, the spectinomycin treatment of the SpecS
GC resulted in alterations in the abundance of proteins involved
in energy metabolism and detoxification, as well as cell envelope
proteins (Rmp and ABC transporter substrate-binding protein).
Based on the obtained proteomic comparisons, a mode of
spectinomycin action on GC is proposed but not experimentally
validated (Nabu et al., 2014). Briefly, in the presence of sub-
minimal inhibitory concentrations, the drug destabilizes the
outer membrane, recruiting Rmp to maintain the integrity of
the cell envelope. Spectinomycin accumulates in the periplasm,
generating a concentration imbalance between the inside and
outside of the cell. In response, significant changes in energy
metabolism including an increase in NADH production and
oxidation through the electron transport chain occur. At the same
time, additional proton motive force allows more drug molecules
to enter the cell. Increased NADH oxidation leads to an increase
in reactive oxygen species, which are detoxified by the increase in
peroxiredoxin and glutamate dehydrogenase production. Higher
levels of L7/L12 allow the cell to overcome the inhibition of
ribosomal translocation imposed by spectinomycin. In the SpecR
strain, amino acid ATP binding cassette transporter substrate-
binding protein levels are decreased even in the absence of
spectinomycin, possibly affecting uptake of the drug. Expression
of enolase is decreased, which may result in increased levels of
2P-D-glycerate and 3P-D-glycerate. Together with an increase in
cysteine synthetase expression, this may improve the cell’s defense
against reactive oxygen species. Finally, the already high levels of
EF-Tu and –Ts, together with the upregulation of L7/L12, may
assist with protein translation in the presence of spectinomycin
(Nabu et al., 2014).
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Future research may be able to exploit some of the suggested
secondary pathways and increase the efficacy or reduce the
resistance potential of future antimicrobial compounds. Also
apparent in this study are some of the shortcomings of 2D SDS-
PAGE, which has limited utility when dealing with low abundance
and/or membrane proteins.
HOW DID THE HEALTH-OBSESSED
RESEARCHER COMPARE TWO
PROTEIN SHAKES?
WITH QUANTITATIVE PROTEOMICS
In contrast to qualitative proteomics, quantitative proteomic
approaches allow for (absolute or relative) quantification of
proteins on a global scale. The object of quantitative proteomics
is to identify specific alterations between control samples and
particular experimental conditions (e.g., healthy versus diseased
state). In addition, quantitative proteomic profiling may focus on
a specific subset of proteins (subproteome), where for instance
bacterial whole cell lysates are subjected to fractionation to
enrich for cell envelope proteins. Very often the proteins of
interest are relatively low in abundance; therefore it is critical to
utilize appropriate combinations of pre-fractionation techniques
such as different kinds of liquid chromatography (affinity,
reversed phase, size-exclusion, or ion exchange) to reduce
the complexity of analyzed samples, in addition to employing
sensitive mass spectrometry instruments. Different approaches
have been developed to facilitate quantitative proteome profiling
studies involving stable isotope labeling, such as ICAT, ICPL,
SILAC, iTRAQ, TMT, and IPTL. In addition, label-free statistical
methodologies (MRM, SWATH) and absolute quantification
methods by mass spectrometry (AQUA strategy) have become
available (reviewed in Chahrour et al., 2015).
Quantitative proteomic approaches, involving different stable
isotope labels and summarized in Table 1, have been used to
investigate how GC responds to oxidative stress (Wu et al.,
2010), transitions from planktonic to biofilm growth (Phillips
et al., 2012), and adapts the composition of the cell envelope in
response to different environmental cues encountered in micro-
ecological niches within the host (Zielke et al., 2015). In addition,
iTRAQ technology has also revealed the dynamic subproteomes
of cell envelopes and naturally released membrane vesicles in four
different GC isolates (Zielke et al., 2014).
WHAT HAPPENS WHEN TWO OXEN GO
ON THEIR FIRST DATE?
OXIDATIVE STRESS
In a typical inflammatory response to GC, neutrophils are
recruited to the site of infection by chemokines, such as IL-
8, released by infected mucosal surfaces (Criss et al., 2009).
When activated neutrophils phagocytize GC, the production of
reactive oxygen species (ROS) is either stimulated or inhibited,
depending on GC expression of opacity-associated proteins
(Opa). Cells expressing Opa protein (Opa+) ligate to human
carcinoembryonic antigen-related cell adhesion molecules
(CEACAMs), specifically CEACAM3, on the surface of the
neutrophil, triggering phagocytosis, NADPH subunit assembly,
and degranulation (Schmitter et al., 2007; Sarantis and Gray-
Owen, 2012). Additionally, Opa57 protein ligated to CEACAM3
amplifies the inflammatory response by activating nuclear factor
(NF)-kB and increasing phosphorylation of the p38 kinase
(Sintsova et al., 2014).
This cascade of ROS production puts the GC cells under
tremendous oxidative stress. However, viable GC has been shown
to survive and replicate within neutrophils, even after NADPH
oxidase activation (Simons et al., 2005), indicating that GC is able
to protect itself against oxidative stress. This pathogen can defend
against superoxide radicals (Tseng et al., 2001) and hydrogen
peroxide (Seib et al., 2004) in a manganese (Mn) dependent
manner. A study combining transcriptomic and qualitative-
and quantitative-proteomic approaches examined the protective
mechanism utilized by GC in the presence of Mn (Wu et al.,
2010). One-dimensional sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (1D SDS-PAGE) paired with one-dimensional
liquid chromatography-tandem mass spectrometry (1D LC-
MS/MS) identified 46 proteins expressed only in the presence of
Mn. Notably, bacterioferritin, azurin (Laz), and iron-superoxide
dismutase (SodB)—proteins involved in defense against oxidative
stress—were expressed in bacteria cultured in the presence of
Mn, but were not detected in those cultured without Mn. When
cultured in the absence of Mn, GC was found to express an outer
membrane methionine sulfate reductase that is also involved in
defense against superoxide and hydrogen peroxide.
Further, a quantitative proteomic investigation using Isotope-
Coded Affinity Tag (ICAT) labeling was used to determine which
proteins were differentially regulated by the presence or absence
of Mn (Wu et al., 2010). For ICAT analysis, two protein samples
are labeled with reactive groups (biotinylated iodoacetamide or
acrylamide derivatives) that specifically react with the sulphydryl
groups of denatured peptides’ cysteine side chains (Gygi et al.,
1999). One sample is labeled with a light isotope, while the
other sample is labeled with a heavy isotope. The samples are
then combined and analyzed by mass spectrometry (Figure 1B;
Table 1). The protein populations can then be quantified by
comparing the ratio of heavy to light proteins (Gygi et al., 1999;
Colangelo and Williams, 2006; Chahrour et al., 2015).
In this study, ICAT labeling, coupled with MS/MS, revealed
numerous proteins that were downregulatedmore than 1.5-fold in
the presence of Mn, including PilT (an ATPase involved in pilus
disassembly), OmpR, a 64 KDa outer membrane protein (OMP
P64k), and peroxiredoxin, which reduces and detoxifies peroxides
(Seib et al., 2006). Additionally, Mn affected the levels of pilin,
superoxide dismutase, and pyrophosphatase without causing a
corresponding change in the transcript level, indicating that these
proteins are likely to be regulated post-transcriptionally by the
presence of Mn (Wu et al., 2010).
Taken together, the results of this study suggest that,
in the presence of Mn, GC upregulates the expression of
iron storage proteins that protect against oxidative damage.
Concomitantly, the bacterium downregulates pyrophosphatase
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TABLE 1 | Quantitative Proteomic Approaches utilized to studying GC.
Proteomic Approach Principles Use in GC References
Isotope coded affinity tag (ICAT) - Post-harvest labeling Response to oxidative stress Wu et al. (2010)
- Heavy or light isotopic reactive groups label cysteine residues in a
protein sample.
- Two samples are pooled and analyzed by MS.
- Relative quantification of proteins by comparing heavy: light ratio.
Stable isotope labeling by amino - Metabolic labeling Shift from planktonic to biofilm Phillips et al. (2012)
acids in cell culture (SILAC) - Growth medium is supplemented with either light (unlabeled) or
heavy (labeled) amino acid.
growth
- Two samples are pooled and analyzed by MS.
- Relative quantification of proteins by comparing heavy: light ratio
isobaric Tagging for Relative and - Post-harvest labeling Cell envelopes and membrane Zielke et al. (2014);
Absolute Quantification (iTRAQ) - Proteolytically digested proteins are tagged on N-termini
and lysine side chains with isobaric mass labels.
vesicles
Comparison of cell envelope Zielke et al. (2015)
- Two to eight samples are pooled and analyzed by MS. profiles upon environmental
- Relative or absolute quantification of proteins by measuring
intensity of reporter ion peak.
cues encountered in the host
(Ppa) and polyphosphate kinase (Ppk). Ppa hydrolyzes inorganic
pyrophosphate (PPi) into two molecules of orthophosphate (Pi),
while Ppk synthesizes polyP from Pi. When these two proteins
are downregulated, PPi accumulates in the cell and chelates Mn.
In a Mn(II)-PPi complex, Mn is able to defend against ROS
non-enzymatically (Wu et al., 2010).
The information gleaned from these proteomic experiments
could suggest a method to combat gonorrhea whereby the
downregulation of protective proteins required only in the
absence of Mn is maintained, but the alteration of the levels
of proteins required for protection from oxidative stress in the
presence of Mn is blocked. Importantly, this study highlights the
utility of proteomic approaches to investigate biological responses
involving post-transcriptional regulation that genomic methods
alone cannot discover. It is important to keep in mind, however,
that ICAT has two major drawbacks: (1) proteins that do not have
any cysteine residues will be eliminated from this analysis, and (2)
the release of biotinylated peptides from the streptavidin column
is not quantitative for low-abundance peptides (Chahrour et al.,
2015).
WHAT IS A MICROBIOLOGIST’S FAVORITE
KIND OF MOVIE?
A BIOFILM
Bacteria often shift from planktonic (free living bacteria) growth
to a biofilm community, where bacteria grow in close proximity
to each other, protected by an extracellular polymer composed
of polysaccharides, proteins, nucleic acids, and lipids (Flemming
and Wingender, 2010). GC has been shown to form biofilms in
vitro (Greiner et al., 2005), and an examination of primary cervical
epithelial cells from cervical biopsy samples revealed biofilm
growth in culture positive gonorrhea cases (Steichen et al., 2008).
Biofilms exacerbate antibiotic resistance by providing a protective
barrier against antimicrobial action, and biofilms formed by GC
are thought to contribute to asymptomatic infections (Steichen
et al., 2008).
To understand the mechanisms underlying biofilm formation,
a quantitative proteomic study examined the proteome changes
GC undergoes in the transition from planktonic to biofilm growth
using stable isotope labeling by amino acids in cell culture (SILAC;
Figure 1C; Table 1; Phillips et al., 2012). One of the important
advantages of SILAC over other stable isotope labeling methods
is that the label is integrated into the peptide at early stages of
experimentation when the sample is metabolically active. Thus,
possible variability due to sample preparation and purification
losses are eliminated (Chahrour et al., 2015).
In this analysis, planktonic cells of GC strain 1291, which is
an arginine auxotroph, were grown with labeled 13C6-Arg, and
biofilm cells were grown with unlabeled Arg in a continuous-
flow apparatus. Extracted protein samples from each bacterial
population were combined and subjected to MALDI-TOF mass
spectrometry analysis. Overall, this global analysis identified 757
proteins, 152 of which were significantly differentially expressed.
In particular, GC cultured in a biofilm exhibited 73 upregulated-
and 54 downregulated-proteins when compared to planktonic
growth. The results of this study indicated that the bacteria
upregulate proteins to respond to an oxygen-limited environment,
including cytochrome c oxidase subunit III CcoP and nitrite
reductase AniA. To cope with restricted nutrient availability in
the biofilm, bacterial metabolism is shifted to increase sugar
fermentation and tricarboxylic acid (TCA) cycle enzymes. The
composition of the outer membrane is also altered during growth
in a biofilm, with increased levels of 9 proteins including OpaB
andOpaD (Phillips et al., 2012), both of which have been shown to
adhere to and damage fallopian tubemucosa (Dekker et al., 1990).
Among the downregulated proteins in the biofilm were proteins
involved in energy metabolism, protein fate and synthesis, and
transport and binding proteins, specifically iron complex outer
membrane receptor protein (FetA) as well as transferrin-binding
protein B and A (TbpB and TbpA, respectively).
A direct comparison of the transcriptome (Falsetta et al.,
2009) and proteome expression profiles of GC biofilms showed
a very poor correlation with only seven overlapping hits
including AniA, OpaB, cytochrome C peroxidase CcpR, putative
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dihydrolipoamide dehydrogenase, putative cysteine synthase/
cystathionine beta-synthase, hypothetical protein NGO0905, and
putative ABC transporter NGO1494 (Phillips et al., 2012).
This study gives insight into the adaptations necessary for GC
to establish long-term infections and emphasizes the utility of
proteomic approaches to examine these adaptations. In addition,
the identified upregulated outer membrane proteins may be
utilized as biomarkers for gonorrhea diagnostics.
WHAT BOOK-LIKE CANDIDATE WAS NOT
AT THE LAST PRESIDENTIAL DEBATE?
A NOVEL VACCINE CANDIDATE
Perhaps one of the most exciting uses of proteomic approaches
is in the search for new ways to combat multidrug resistant
GC. We are applying a proteomics-driven reverse vaccinology
approach to identify vaccine candidate proteins against gonorrhea
(Zielke et al., 2014, 2015). Reverse vaccinology searches for
possible vaccine candidate proteins using different genomics
and proteomics methodologies and has already been successfully
applied to different pathogenic bacteria including N. meningitidis
serogroup B (Heckels and Williams, 2010; Adamczyk-Poplawska
et al., 2011; Seib et al., 2012; Delany et al., 2013; Heinson et al.,
2015).
No vaccine against GC currently exists, although research has
been ongoing for decades. Two attempted vaccines, comprised
of killed whole cells and purified pilin protein, failed in clinical
trials over 13 years ago (Zhu et al., 2011). Since that time, very
little research into gonorrheal vaccines has occurred, mainly
due to the highly variable targeted surface proteins. Because
GC is a strict human pathogen, research was also hampered
by the lack of a suitable small animal model for gonorrheal
infection (Jerse et al., 2014). Fortunately, a mouse model of female
infection was developed, in which female mice are treated with
17-b-estradiol when they are in the diestrus stage of the estrus
cycle. The mice are also treated with an antibiotic cocktail of
streptomycin sulfate, vancomycin HCl, and trimethoprim sulfate
to prevent overgrowth of commensal vaginal bacteria while under
the influence of estradiol. 2 days after estradiol treatment, GC is
introduced intravaginally. Using this model, GC can be recovered
an average of 12.2 days post-inoculation with 106 colony forming
units (Jerse, 1999). A further advancement in the mouse model
has been the development of transgenic mice that express human
CEACAMproteins, providing a closer reproduction of conditions
encountered in the human host (Jerse et al., 2014). The availability
of a mouse model has greatly facilitated vaccine research. The
immune response to infection, as well as resistance to subsequent
infections after inoculation with an experimental vaccine can be
closely monitored and investigated with the genetic tools available
for studying mice (Zhu et al., 2011). However, to fully utilize
this model for vaccine research, suitable candidate proteins must
be identified—a goal for which proteomic approaches are ideally
suited.
During the development of the MenB vaccine, out of nearly
600 candidates selected by reverse vaccinology, 350 recombinant
proteins were successfully expressed in Escherichia coli and
evaluated for their surface exposure. A total of 28 among them
elicited bactericidal antibodies against Group B meningococci
in vitro. Finally, the neisserial heparin-binding antigen NHBA,
factor H-binding protein fHbp, as well as the neisserial adhesin
NadA were chosen as part of the MenB vaccine (Seib et al., 2012;
Delany et al., 2013; Jerse et al., 2014). In contrast, only 12 different
candidates are being evaluated as potential gonorrhea vaccine
antigens (Jerse et al., 2014). Therefore, a more far-reaching effort
is required to make a gonorrhea vaccine a reality.
Of particular interest for vaccine development and
identification of new drug targets are proteins localized to the
bacterial cell envelope and membrane vesicles (MVs)—spherical
outpouchings of the cell envelope—as they interact directly or
indirectly with host tissues; play roles in pathogenesis, antibiotic
resistance, and biofilm formation; and participate in general
physiological processes. Surprisingly few studies addressed GC
cell envelope composition (Yoo et al., 2007; Phillips et al., 2012;
Zielke et al., 2014). Also, despite studies reporting the release of
MVs and their different morphological forms (spherical, lobed,
and tubular) in GC from the early 1970s, only a few reports
focused on elucidating their components (Swanson et al., 1971;
Dorward et al., 1989; Pettit and Judd, 1992a,b; Falsetta et al., 2011;
Zielke et al., 2014).
To begin the systematic mining of GC cell envelope and
MVs for the discovery of vaccine and drug candidates, we
first used the PSORTb 3.0.2 (Gardy et al., 2005) bioinformatics
predictions and analyzed the subcellular localization of all ORFs
in the completed genome sequence of strains FA1090 (Gen
Bank accession number AE004969) and NCCP11945 (Gen Bank
accession number CP001050), as well as the draft genome
sequences of 14 different GC strains (downloaded from the
Broad Institute website3). These studies revealed that, on average,
about 50 of the 2,000 ORFs present in the GC genome encode
outer membrane proteins (Zielke and Sikora, 2014). However,
the subcellular location could not be predicted for about 30% of
all ORFs. This analysis demonstrated that there is still much to
learn about GC cell envelope composition and opened up exciting
prospects for applying proteomics for the discovery of vaccine
targets.
As proteomic investigations of membrane proteins are
technically challenging, we chose to apply gel-free quantitative
proteomic approaches including isobaric tagging for relative
and absolute quantification (iTRAQ, Table 1) combined with
multidimensional liquid chromatography and tandem mass
spectrometry (2D-LC/MS/MS) to examine cell envelopes and
naturally released MVs (Zielke et al., 2014). Four GC strains:
FA1090, F62, MS11, and 1291 were cultured in liquid media
under standard growth conditions and their cell envelopes and
MVs were harvested in mid-logarithmic phase of growth. iTRAQ
quantification was performed by labeling proteins isolated from
subproteome fractions of each strain of interest with one of four
isobaric tags (N-hydroxysuccinimide ester-activated compounds)
that react to free amine groups on the N-termini and lysine side
chains of proteins with high efficiency (Ross et al., 2004). Each of
3http://www.broadinstitute.org/annotation/genome/neisseria_gonorrhoeae/
MultiHome.html
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the four tags contains a reporter ion of a unique mass (Figure 1D;
Table 1). When the samples are combined and subjected to mass
spectrometry, the reporter ions are released from the labeled
peptide. After the release of the reporter ions, all of the identical
peptides in a sample will result in identical mass spectra, and the
abundance of the peptide in the four multiplexed samples can be
quantified by the relative intensity of the corresponding reporter
ion peak (Ross et al., 2004; Wiese et al., 2007). The advantage
of using iTRAQ is that it can be easily multiplexed and up to
8 different samples can be simultaneously analyzed within a
single experiment. Additionally, as the iTRAQ tags react with all
primary amine functional groups of peptides, nearly all peptides
are labeled and information about not only their abundance but
also their modification(s) can be acquired (Chahrour et al., 2015).
Our proteomic profiling of cell envelopes and native MVs
revealed 533 and 168 common proteins, respectively, in analyzed
GC strains. A total of 22 differentially abundant proteins were
discovered including hitherto unknown proteins. Among those
proteins that displayed similar abundance in four GC strains, we
identified 305 and 46 cell envelope-and MVs-associated proteins,
respectively. In addition, 34 proteins were found in both cell
envelopes and MVs with eleven of them differentially regulated
(Zielke et al., 2014). A few of these differentially expressed
proteins included cytoplasmic proteins, an observation that was
confirmed by a subsequent, independent proteomic study of MVs
(Perez-Cruz et al., 2015).
The ubiquitous outer membrane proteins identified included
GC homologs of the outer membrane b-barrel assembly (Bam)
protein complex (Ricci and Silhavy, 2012), including BamA,
BamD, and BamE; lipopolysaccharide transport protein LptD;
and TamA (NGO1956) and TamB (NGO1955), two proteins
thought to work cooperatively to assist in the assembly of
autotransporter proteins (Heinz et al., 2015). Numerous
uncharacterized proteins were also ubiquitously expressed,
including NGO1344, NGO1985, NGO2111, NGO2121, and
NGO2139 (Zielke et al., 2014).
We further examined LptD, NGO1344, NGO1985, NGO2111,
NGO2121, NGO2139, and TamB by constructing conditional-
(LptD) or complete- knockout strains for each protein. These
proteins were chosen because they contain domains predicted
to function in maintaining cell envelope homeostasis. LptD
expression in GC was placed under the control of an isopropyl
b-D-1-thiogalactopyranoside (IPTG)-inducible promoter. This
strain was unable to grow when streaked onto media lacking
IPTG, while it grew robustly on plates supplemented with IPTG.
Further, after 3 h of culturing in liquid media without IPTG,
the bacteria ceased to grow. By 5 h, bacterial viability decreased
dramatically (nearly 13-fold) compared to the LptD-expressing
strain. These experiments indicated that LptD is likely essential
forGC viability. To test whetherNGO1344,NGO1985,NGO2111,
NGO2121, NGO2139, and TamB play functions in the integrity of
the GC cell envelope, the individual clean deletion mutants were
constructed in strain FA1090 and spotted on plates supplemented
with various compounds. Although the loss of these proteins
had no effect on bacterial growth under permissive conditions,
the loss of NGO1985 resulted in a severe growth defect in the
presence of bile salts, polymyxin B, Tween 20, SDS, urea, and
chloramphenicol. Further, these phenotypes could be completely
reversed by complementation with an IPTG-inducible version
of the ngo1985 gene. Additionally, NGO2121 exhibited reduced
growth in the presence of bile salts and polymyxin B. These
proteins, identified by quantitative proteomic approaches, appear
to provide an important function in maintaining cell membrane
integrity and, as such, are promising targets for development of
new therapeutic interventions against GC (Zielke et al., 2014).
To continue this research endeavor, we went on to determine
the ubiquitously and specifically expressed cell envelope proteins
of GC FA1090 challenged with host-relevant environmental
stimuli: oxygen availability, iron deprivation, and the presence of
human serum (Zielke et al., 2015). A myriad of novel proteins
have been identified. Our initial characterization of five novel
vaccine candidates that were ubiquitously expressed under these
different growth conditions demonstrated that BamA, LptD,
TamA, NGO2054, and NGO2139 were surface exposed and
produced bactericidal antibodies that cross-reacted with a panel
of diverse GC isolates. These promising results strongly suggest
that the proteomics-driven approach will provide a foundation
for the development of anti-GC vaccine(s), which would be
the ideal way to prevent gonorrhea. Finally, to promote the
utilization of the newly identified proteins and the knowledge of
the GC subproteome dynamics among the scientific community,
our entire data sets from all these investigations were made
publicly available via the ProteomeXchange Consortium4, the
PRIDE partner repository ProteomeXchange with the identifiers
PXD000549 and PXD001944.
FUTURE DIRECTIONS
Although proteomic approaches have revealed a multitude of
information on the physiology of GC, to formulate an effective
vaccine, more information needs to be gathered about the way
its surface proteins interact with host cells during an infection.
Ideally, the proteome of clinical samples that have never been
subcultured should be examined to determine which proteins
are expressed during different stages of infection. This approach
presents a significant technical challenge to overcome, as sufficient
bacterial material must be collected for a quantitative proteomic
analysis. In our investigation of the cell envelope and MV
proteome, we collected material from 1 liter of culture (Zielke
et al., 2014). Although other proteomic studies have used less
material, including 5 milliliters of culture (Wu et al., 2010) or
bacteria harvested from 20 plates (Anonsen et al., 2012; Perez-
Cruz et al., 2015) collecting this amount of sample from a patient
is not feasible; more sensitive MS analyzers or alternate methods
of sample enrichment will be required. These studies will give
insight into the proteomic adaptations the bacteria undergo to
establish and maintain infection. Information collected from
proteomic studies of clinical samples and host tissue culture can
help further drive vaccine development and have the potential
to aid in the discovery of stably expressed protein targets of
antimicrobial agents with novel modes of action. Integration of
multiple approaches, including public access to on-line raw data
4http://www.proteomexchange.org
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is essential if there is to be a sense of participation across the
biomedical research community.
An interesting analysis technique was recently pioneered
by Altindis et al. (2015). Termed “protectome analysis,” their
technique searches for vaccine candidate proteins in proteomic
datasets by identifying proteins with structural or functional
features in common with proteins known to provide protection.
This analysis tool could be used in combination with other
proteomic studies to immediately identify proteins expressed
during infection with the potential to provide protection against
reinfection.
As more information is deposited into proteomic databases,
the utility of proteomic approaches to identify GC in clinical
samples will increase. For example, in cases where the molecular
determinant of antimicrobial resistance is known, proteomic
approaches have the potential to immediately recognize the
protein modification(s) that result in antimicrobial resistance,
a feat that is not possible with current NAAT identification
techniques.
Finally, proteomic investigations ofmultidrug resistance strains
can reveal the mode of drug action, as well as the pathway(s)
the bacterium uses to resist multiple antibiotics. One mystery
that proteomic approaches may be able to solve is the identity
of “Factor X,” an unknown determinant of penicillin and
cephalosporin resistance that is non-transformable and therefore
is difficult to study with typical genetic methods (Unemo and
Shafer, 2014).
CONCLUSION
Developing novel vaccines or antimicrobial agents is critical
in the face of growing antibiotic resistance, and global and
quantitative proteomic approaches have begun to reveal potential
targets in the fight against GC. Proteomic approaches are
ideal for the discovery of vaccine candidate proteins, as well
as protein targets for the development of novel antimicrobial
agents. Qualitative proteomic studies revealed the GC defense
response to spectinomycin, while quantitative proteomics have
demonstrated bacterial adaptations to conditions encountered
in the host, including oxidative stress, anoxia, iron deprivation,
and the presence of human serum. Proteomics have also been
recently adapted to identify GC in clinical samples, which can
expedite treatment. Importantly for vaccine development, stably
expressed proteins have been identified through high-throughput
examinations of cell envelopes and naturally released MVs.
These proteomic studies will act as starting points for studies
into structural vaccinology, protein–protein interactions, and GC
physiology, and have already given new insights into ways to
combat this important, difficult to treat pathogen.
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